Dna X (SONM) Receivables - Other (2020 - 2026)

Dna X's Receivables - Other history runs 7 years deep, the most recent figure standing at -$5.5 million for Q1 2026.

• Quarterly Receivables - Other fell 185.09% year-over-year to -$5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$136000.0 (down 102.11% YoY) and the FY2025 annual result came in at -$181000.0, down 200.0% from the prior year.
• Receivables - Other was -$5.5 million for Q1 2026 at Dna X, down from $9.8 million in the prior quarter.
• Across five years, Receivables - Other topped out at $9.8 million in Q3 2025 and bottomed at -$5.5 million in Q1 2026.
• A 5-year average of $2.7 million and a median of $1.9 million in 2022 frame the typical range for Receivables - Other.
• Annual changes were most pronounced in 2024 — Receivables - Other jumped 365.73% — and 2026, when it sank 185.09%.
• Dna X's Receivables - Other stood at $2.3 million in 2022, then plunged by 57.65% to $961000.0 in 2023, then tumbled by 148.18% to -$463000.0 in 2024, then soared by 2225.49% to $9.8 million in 2025, then slumped by 155.79% to -$5.5 million in 2026.
• Business Quant data shows SONM's Receivables - Other at -$5.5 million in Q1 2026, $9.8 million in Q3 2025, and $7.0 million in Q2 2025.